JPMorgan Chase & Co. Sells 20,279 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

JPMorgan Chase & Co. lowered its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 19.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,630 shares of the life sciences company's stock after selling 20,279 shares during the period. JPMorgan Chase & Co. owned about 0.11% of Integra LifeSciences worth $1,574,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IART. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth approximately $44,153,000. Dimensional Fund Advisors LP raised its stake in shares of Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company's stock valued at $52,014,000 after buying an additional 12,766 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Integra LifeSciences by 15.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock valued at $17,158,000 after buying an additional 125,620 shares during the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Integra LifeSciences by 64.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company's stock worth $24,925,000 after acquiring an additional 335,557 shares during the period. Finally, Glenmede Trust Co. NA increased its holdings in Integra LifeSciences by 125.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company's stock worth $13,224,000 after acquiring an additional 405,624 shares during the last quarter. Institutional investors own 84.78% of the company's stock.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company's stock, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.10% of the company's stock.

Integra LifeSciences Price Performance

NASDAQ IART traded up $0.45 during trading on Friday, reaching $26.05. The company's stock had a trading volume of 551,282 shares, compared to its average volume of 583,305. The firm has a fifty day moving average of $23.32 and a 200 day moving average of $22.37. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The stock has a market capitalization of $2.01 billion, a PE ratio of -289.41, a P/E/G ratio of 0.83 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million for the quarter, compared to analysts' expectations of $375.81 million. During the same period in the prior year, the business earned $0.76 earnings per share. Integra LifeSciences's revenue for the quarter was down .4% compared to the same quarter last year. Analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the topic of several recent research reports. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective for the company. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Finally, Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research note on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.